Comparative Pharmacology
Head-to-head clinical analysis: EMEND versus METOZOLV ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMEND versus METOZOLV ODT.
EMEND vs METOZOLV ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
None Documented
None Documented
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Antiemetic
Antiemetic